Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1303-1306

  Krens, L L ^a   Baas, J M ^a   Verboom, M C ^a   Paintaud, G ^b   Desvignes, C ^b   Guchelaar, H J ^a   Gelderblom, H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Cetuximab; Pharmacokinetics; Renal dysfunction

Indexed keywords

CETUXIMAB; CLEMASTINE;

AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; GLOMERULUS FILTRATION RATE; HALLUCINATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MEDICAL HISTORY; OSTEOSARCOMA; PRIORITY JOURNAL;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; OSTEOSARCOMA; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 84903814243     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2462-4     Document Type: Article

References (10)

1. Blick SK, Scott LJ (2007) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 67(17):2585-2607 (Pubitemid 350159168)
2. Thariat J, Azzopardi N, Peyrade F, Launay-Vacher V, Santini J, Lecomte T et al (2008) Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J Clin Oncol 26(25):4223-4225
3. Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S et al (2007) Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 72(3-4):209-210 (Pubitemid 351161612)
4. Aldoss IT, Plumb T, Zhen WK, Lydiatt DD, Ganti AK (2009) Cetuximab in hemodialysis: a case report. Head Neck 31(12):1647-1650
5. Fontana E, Pucci F, Ardizzoni A (2014) Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab. Anticancer Drugs 25(1):120-122
6. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M et al (2012) Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 18(2):432-441
7. Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A et al (2011) Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 17(19):6329-6337
8. Ceze N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E et al (2009) An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit 31(5):597-601
9. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S et al (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12(21):6517-6522 (Pubitemid 44799726)
10. Fracasso PM, Burris H III, Arquette MA, Govindan R, Gao F, Wright LP et al (2007) A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13(3):986-993 (Pubitemid 46340377)